Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance-Reference-Cited by-同舟云学术

Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance

Published:2018-06-29 Issue:9 Volume:46 Page:1285-1303
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Kenny Jane R.,Ramsden Diane,Buckley David B.,Dallas Shannon,Fung Conrad,Mohutsky Michael,Einolf Heidi J.,Chen Liangfu,Dekeyser Joshua G.,Fitzgerald Maria,Goosen Theunis C.,Siu Y. Amy,Walsky Robert L.,Zhang George,Tweedie Donald,Hariparsad Niresh

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference36 articles.

1. Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model

2. Limit of blank, limit of detection and limit of quantitation;Armbruster;Clin Biochem Rev,2008

3. THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

4. Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

5. Comparison of different approaches to predict metabolic drug-drug interactions

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An open‐label study to explore the optimal design of CYP3A drug–drug interaction clinical trials in healthy Chinese people;Pharmacology Research & Perspectives;2024-07-28

2. Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic;Drug Metabolism Reviews;2024-07-26

3. Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges;Clinical Pharmacokinetics;2024-06-18

4. Human Pharmacokinetic and CYP3A Drug–Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment;Drug Metabolism and Disposition;2024-05-29

5. Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach;Clinical Pharmacology in Drug Development;2024-05-16